The Royal College of Radiologists partnered with the British Nuclear Medicine Society to convene a roundtable discussion addressing molecular radiotherapy research priorities across the UK, OncoDaily reported.
The meeting brought together key partners driving molecular radiotherapy research to examine barriers and outline necessary steps for patient access, following the National Cancer Plan for England’s designation of the treatment as a research priority.
The agency said that it looks forward to sharing the outcomes of these discussions in the new year.
“This is excellent. Really important work for The Royal College of Radiologists to be leading on with British Nuclear Medicine Society,” said Chris Jones, CRUK Clinician Scientist and Assistant Research Professor at the University of Cambridge.
Dr. Chris Jones serves as a CRUK Clinician Scientist Fellow, Junior Group Leader, and Co-Director of the CRUK Cambridge RadNet Radiation Research Centre of Excellence.
He is also a Loke Medical Sciences Fellow, Director of Studies in Medicine at King’s College Cambridge, and an Honorary Consultant Clinical Oncologist at Addenbrooke’s Hospital. His primary research explores the ways in which gastric and oesophageal cancers resist therapies and adapt to treatment.
Dr. Jones completed his medical training at the University of Birmingham in 2013, where he received the Vice Chancellor’s Prize. He subsequently worked on the Academic Foundation Programme in Birmingham before joining the University of Leeds in 2015 for an NIHR Academic Clinical Fellowship in Clinical Oncology.
By 2022, Dr. Jones moved to the University of Cambridge to begin a Clinical Lectureship. During this time, he was based between the Cambridge CRUK Radiation Research Centre of Excellence and the Early Cancer Institute within Professor Rebecca Fitzgerald’s group.
His work there investigated tumour evolution, therapy response, and the heterogeneity of oesophageal adenocarcinoma. In 2026, he established his own research group at the Early Cancer Institute after receiving a CRUK Clinician Scientist Fellowship and the Loke Medical Sciences Fellowship.
The Royal College of Radiologists partnered with the British Nuclear Medicine Society to convene a roundtable discussion addressing molecular radiotherapy research priorities across the UK, OncoDaily reported. As the professional body responsible for clinical oncology and clinical radiology throughout the United Kingdom, the Royal College of Radiologists serves to advance the science and practice of these specialties while setting and monitoring the educational curriculum and professional standards for practitioners.
Through its Faculty of Clinical Oncology, the organization works to improve patient access by defining the clinical requirements for emerging treatments and ensuring that doctors are trained to meet rigorous national benchmarks, ultimately shaping the future of radiotherapy delivery and research across the country.
His current research aims to develop kinder, more effective treatments that support early detection strategies. Specifically, his group studies targeted radionuclide therapy as a novel approach to radiotherapy, intending to improve patient outcomes by addressing disease heterogeneity.